Time and Diffusion Lesion Size in Major Anterior Circulation Ischemic Strokes
暂无分享,去创建一个
R. Gonzalez | W. Copen | L. Schwamm | P. Schaefer | A. Yoo | Julian He | M. Lev | G. Papini | B. Vachha | R. Hakimelahi | M. Higazi | R. González | E. GiacomoD. | Papini | W. Pamela | Schaefer
[1] G. Zaharchuk,et al. Hypoperfusion Intensity Ratio Predicts Infarct Progression and Functional Outcome in the DEFUSE 2 Cohort , 2014, Stroke.
[2] R. Gonzalez,et al. Good Outcome Rate of 35% in IV-tPA–Treated Patients With Computed Tomography Angiography Confirmed Severe Anterior Circulation Occlusive Stroke , 2013, Stroke.
[3] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[4] F. Nicoli,et al. Perfusion-Weighted Imaging–Derived Collateral Flow Index is a Predictor of MCA M1 Recanalization after IV Thrombolysis , 2013, American Journal of Neuroradiology.
[5] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[6] L. Schwamm,et al. Rapid identification of a major diffusion/perfusion mismatch in distal internal carotid artery or middle cerebral artery ischemic stroke , 2012, BMC Neurology.
[7] Manabu Inoue,et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study , 2012, The Lancet Neurology.
[8] Z. Chaudhry,et al. Infarct Volume Is a Pivotal Biomarker After Intra-Arterial Stroke Therapy , 2012, Stroke.
[9] Wade S. Smith,et al. Effect of Time to Reperfusion on Clinical Outcome of Anterior Circulation Strokes Treated With Thrombectomy: Pooled Analysis of the MERCI and Multi MERCI Trials , 2011, Stroke.
[10] Geoffrey A. Donnan,et al. Refining the Definition of the Malignant Profile: Insights From the DEFUSE-EPITHET Pooled Data Set , 2011, Stroke.
[11] A. Abou-Chebl,et al. Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients , 2010, Stroke.
[12] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[13] A. Sorensen,et al. Stability of large diffusion/perfusion mismatch in anterior circulation strokes for 4 or more hours , 2010, BMC neurology.
[14] J. Broderick,et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent , 2009, Neurology.
[15] Jeffrey L Saver,et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.
[16] R. Gonzalez,et al. MRI-Based Selection for Intra-Arterial Stroke Therapy: Value of Pretreatment Diffusion-Weighted Imaging Lesion Volume in Selecting Patients With Acute Stroke Who Will Benefit From Early Recanalization , 2009, Stroke.
[17] W. Copen,et al. Existence of the diffusion-perfusion mismatch within 24 hours after onset of acute stroke: dependence on proximal arterial occlusion. , 2009, Radiology.
[18] J. Alger,et al. Determinants of the distribution and severity of hypoperfusion in patients with ischemic stroke , 2008, Neurology.
[19] Joseph P Broderick,et al. National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate , 2008, Stroke.
[20] F Viñuela,et al. Impact of collateral flow on tissue fate in acute ischaemic stroke , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] Jan van Gijn,et al. Clinical practice. Acute ischemic stroke. , 2007, The New England journal of medicine.
[22] P. Kaňovský,et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis , 2006, Neuroradiology.
[23] Steven Warach,et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.
[24] R. Gonzalez,et al. Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain". , 2006, AJNR. American journal of neuroradiology.
[25] J. Saver. Time Is Brain—Quantified , 2006, Stroke.
[26] D. Liebeskind. Collaterals in acute stroke: beyond the clot. , 2005, Neuroimaging clinics of North America.
[27] G. Christoforidis,et al. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. , 2005, AJNR. American journal of neuroradiology.
[28] Timothy Q. Duong,et al. Perfusion and diffusion imaging in acute focal cerebral ischemia: Temporal vs. spatial resolution , 2005, Brain Research.
[29] J. Martí-Fàbregas,et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke , 2005, Neurology.
[30] G Schlaug,et al. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001, Neurology.
[31] T. Neumann-Haefelin,et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. , 2000, Stroke.
[32] A. Furlan,et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.
[33] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[34] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[35] P Trouillas,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.
[36] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.